These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 31695800)

  • 21. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine?
    Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R
    Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology].
    Schaefer N; Prior J
    Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies.
    Khodabakhsh F; Behdani M; Rami A; Kazemi-Lomedasht F
    Int Rev Immunol; 2018; 37(6):316-322. PubMed ID: 30741045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Domain Antibody Theranostics on the Horizon.
    Wei W; Younis MH; Lan X; Liu J; Cai W
    J Nucl Med; 2022 Oct; 63(10):1475-1479. PubMed ID: 35835579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanobodies as Versatile Tool for Multiscale Imaging Modalities.
    Erreni M; Schorn T; D'Autilia F; Doni A
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33353213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
    Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
    Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
    Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
    Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theranostics Using Antibodies and Antibody-Related Therapeutics.
    Moek KL; Giesen D; Kok IC; de Groot DJA; Jalving M; Fehrmann RSN; Lub-de Hooge MN; Brouwers AH; de Vries EGE
    J Nucl Med; 2017 Sep; 58(Suppl 2):83S-90S. PubMed ID: 28864618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel therapy based on camelid nanobodies.
    Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
    Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Special Issue "Recent Advances in Precision Nanomedicine for Cancer".
    Brignole C; Pastorino F
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobodies: The "Magic Bullets" in therapeutics, drug delivery and diagnostics.
    Mir MA; Mehraj U; Sheikh BA; Hamdani SS
    Hum Antibodies; 2020; 28(1):29-51. PubMed ID: 31322555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy.
    Zhu L; Zhou Z; Mao H; Yang L
    Nanomedicine (Lond); 2017 Jan; 12(1):73-87. PubMed ID: 27876448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
    Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme-Instructed Self-assembly in Biological Milieu for Theranostics Purpose.
    Huang Z; Yao Q; Wei S; Chen J; Gao Y
    Curr Med Chem; 2019; 26(8):1351-1365. PubMed ID: 28933284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
    Ding L; Tian C; Feng S; Fida G; Zhang C; Ma Y; Ai G; Achilefu S; Gu Y
    Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Small molecules as theranostic agents in cancer immunology.
    Li J; Van Valkenburgh J; Hong X; Conti PS; Zhang X; Chen K
    Theranostics; 2019; 9(25):7849-7871. PubMed ID: 31695804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR- and Integrin α
    Rodrigues Toledo C; Tantawy AA; Lima Fuscaldi L; Malavolta L; de Aguiar Ferreira C
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.